HOUSTON, Sept. 22 /PRNewswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CYBX) today announced that its corporate headquarters in Houston, TX has reopened following Hurricane Ike.
The facility incurred no damage from the hurricane, but had been without power for several days, resulting in the Company operating from its disaster recovery facility during that time. All business activities have since returned to normal, including all shipments and production of Cyberonics' Vagus Nerve Stimulation (VNS) Therapy(TM) System.
The Company continues to anticipate that there will be no material impact on its business as a result of the circumstances brought about by Hurricane Ike.
About Cyberonics, Inc. and VNS Therapy(TM)
Cyberonics, Inc. (Nasdaq: CYBX) is a medical technology company with core expertise in neuromodulation. The company developed and markets the Vagus Nerve Stimulation (VNS) Therapy(TM) System, which is FDA-approved for the treatments of refractory epilepsy and treatment-resistant depression. The VNS Therapy System uses a surgically implanted medical device that delivers pulsed electrical signals to the vagus nerve. Cyberonics markets the VNS Therapy System in selected markets worldwide.
Safe harbor statement
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended and
Section 21E of the Securities Exchange Act of 1934, as amended. These
statements can be identified by the use of forward-looking terminology,
including "may," "believe," "will," "expect," "anticipate," "estimate,"
"plan," "intend," and "forecast," or other similar words. Statements
contained in this press release are based upon information presently
available to us and assumptions that we believe to be reasonable. We are
not assuming any duty to update this information should those facts change
or should we no longer believe the assumptions to be reasonable. Investors
are cautioned that all such statements involve risks and uncertainties,
including without limitation, statements concerning reflecting the Notes as
a long-term liability on our balance sheet and improving shareholder value.
Our actual results may differ materially. Important factors that may cause
actual results to differ include, but are not limited to: continued market
acceptance of VNS Therapy and sales of our product; the development and
satisfactory completion of clinical trials and/or market test and/or
regulatory approval of VNS Therapy for the treatment of other indications;
satisfactory completion of post-market studies required by the U.S. Food
and Drug Administration as a condition of approval for the
treatment-resistant depression indication; adverse changes in coverage or
reimbursement amounts by third-parties; intellectual property protection
and potential infringement claims; maintaining compliance with government
regulations and obtaining necessary government approvals for new
indications; product liability claims and potential litigation; reliance on
single suppliers and manufacturers for certain components; the accuracy of
management's estimates of future expenses and sales; the results of the
previously disclosed governmental inquiries; the potential identification
of material weaknesses in our internal controls over financial reporting;
risks and costs associated with such governmental inquiries and any
litigation relating thereto or to our stock option grants, procedures, and
practices (including the previously disclosed private litigation);
uncertainties associated with stockholder litigation; and other risks
detailed from time to time in our filings with the Securities and Exchange
Commission (SEC). For a detailed discussion of these and other cautionary
statements, please refer to our most recent filings with the SEC, including
our Annual Report on Form 10-K for the fiscal year ended April 27, 2007.
Greg Browne, CFO
100 Cyberonics Blvd.
Houston, TX 77058
Main: (281) 228-7262
Fax: (281) 218-9332
|SOURCE Cyberonics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved